Alzinova

1,684

SEK

+0,72 %

Mindre end 1K følgere

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+0,72%

+2,93%

-9,56%

-48,66%

-51,33%

+5,25%

+0,93%

-78,44%

-76,52%

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market. The company was founded in 2011 and is headquartered in Gothenburg.

Markedsværdi

175,68 mio. SEK

Aktieomsætning

1,11 mio. SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

21.8

2025

Delårsrapport Q2'25

13.11

2025

Delårsrapport Q3'25

26.2

2026

Årsrapport '25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse23.6.2025, 09.59

DNB Carnegie Access: Alzinova: Intervju - Fas II-studie, affärsutveckling och marknadspotential

Selskabsmeddelelse23.6.2025, 05.20

Alzinova provides market update with future sales forecast – strengthened position for phase 2

Selskabsmeddelelse19.6.2025, 06.50

Alzinova’s ALZ-101 vaccine shows new promising results in normalizing protective antibody levels in Alzheimer’s disease patients

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse17.6.2025, 12.50

Alzinova expands analyst coverage through new collaboration with Rx Securities

Selskabsmeddelelse17.6.2025, 06.30

Alzinova selects Worldwide Clinical Trials as CRO partner for Phase 2 study of ALZ-101

Selskabsmeddelelse12.6.2025, 06.30

ALZ-101 immunization generates sustained plasma IgG and predictable CSF antibody levels against neurotoxic oligomers

Pressemeddelelse2.6.2025, 11.52

Alzinova engages in discussions with potential partners and explores development strategies for ALZ-101 at BIO International Convention 2025 in Boston

Selskabsmeddelelse28.5.2025, 11.50

Bulletin from the Annual General Meeting of Alzinova AB (publ)

Pressemeddelelse16.5.2025, 08.39

DNB Carnegie Access: Alzinova: Fully focused on Phase II preparations – Q1 review

Pressemeddelelse15.5.2025, 09.34

Redeye: Alzinova Q1 - Extended financial runway

Selskabsmeddelelse15.5.2025, 08.47

Correction: Alzinova publishes interim report January – March 2025

Selskabsmeddelelse15.5.2025, 06.30

Alzinova publishes interim report January – March 2025

Selskabsmeddelelse9.5.2025, 15.19

Alzinova announces outcome in rights issue

Selskabsmeddelelse30.4.2025, 06.00

The last day of trading in subscription rights in Alzinova’s rights issue

Selskabsmeddelelse24.4.2025, 12.34

Correction: Alzinova publishes annual report for 2024

Selskabsmeddelelse24.4.2025, 11.00

Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial

Selskabsmeddelelse24.4.2025, 06.55

Alzinova publishes annual report for 2024

Selskabsmeddelelse23.4.2025, 17.31

NOTICE OF ANNUAL GENERAL MEETING IN ALZINOVA AB (PUBL)

Selskabsmeddelelse22.4.2025, 15.13

Alzinova has received letters of intent from the Board of Directors, management and existing shareholders in the company's ongoing rights issue of shares of approximately SEK 35.7 million

Selskabsmeddelelse17.4.2025, 06.30

The subscription period in Alzinovas rights issue of shares starts today

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.